DOJ, DEA Reclassify Medical Cannabis to Schedule III Nationwide
DOJ and DEA reclassified FDA-approved and state-licensed medical cannabis to Schedule III on April 23, 2026.
Why it matters: This shift eases federal restrictions, enabling tax deductions and research access for legal professionals, in-house counsel, and regulated businesses operating in states with medical marijuana laws. It also signals a potential path toward broader reform, though recreational cannabis remains federally illegal.
- Order signed April 23, 2026, covers FDA-approved and state-licensed medical marijuana.
- State-licensed businesses gain eligibility for standard tax deductions under Section 280E.
- Expedited DEA registration process now available for state license holders.
- Reclassification does not apply to recreational cannabis, which remains Schedule I.
The Department of Justice and DEA have officially shifted federally recognized medical marijuana products—including FDA-approved and state-licensed offerings—from Schedule I to Schedule III under the Controlled Substances Act, effective April 22, 2026. Acting Attorney General Todd Blanche announced the order on April 23, citing White House priorities to expand treatment options and advance medical research.
- The move opens the door for state-licensed medical marijuana businesses to access ordinary business deductions, previously disallowed under Internal Revenue Code Section 280E—a major relief for operators in the 40 states with legal medical frameworks.
- The DEA has also launched an expedited federal registration process for state-licensed entities, streamlining compliance requirements for these businesses.
- The reclassification is designed to promote "targeted, rigorous research into marijuana's safety and efficacy," according to Blanche, giving both healthcare providers and legal professionals new clarity in advising corporate or in-house clients on compliance.
- Importantly, recreational marijuana is unaffected by this order and remains a Schedule I controlled substance. This means ongoing legal risks and compliance burdens persist for businesses operating in related markets, particularly in the 24 states permitting recreational use.
Paul Armentano, Deputy Director of NORML, acknowledged the change as "historic" but cautioned that it "still falls well short" of comprehensive federal reform (industry analysis).
An expedited DOJ hearing on the broader rescheduling of all marijuana products is set for June 29, 2026, signaling ongoing regulatory attention and possible further changes to federal cannabis law.
By the numbers:
- 40 — States with legalized medical marijuana
- 24 — States with legalized recreational marijuana
- April 22, 2026 — Effective date for the reclassification
Yes, but: Recreational marijuana remains federally illegal, and the current order does not address all criminal penalties or resolve conflicts between state and federal law.
What's next: The DOJ will hold an expedited hearing on June 29, 2026, to consider broader marijuana rescheduling.